Skip to main content

Table 5 Additional known-group comparisons of the Taiwan Chinese EORTC QLQ-C30 and QLQ-CR29

From: Validation of the Taiwan Chinese version of the EORTC QLQ-CR29 to assess quality of life in colorectal cancer patients

Scale Stoma   Surgery   Adjuvant therapy  
Without stomy With stomy P-value& Minimally invasive Laparotomy P-value& Without adjuvant therapy With adjuvant therapy P-value&
n = 97 n = 11   n = 61 n = 42   n = 38 n = 65  
QLQ-C30 function
 QL2 64.1 62.1 0.706 64.3 66.0 0.793 65.7 62.9 0.610
 PF 81.9 81.8 0.516 83.0 82.2 0.447 84.3 80.5 0.143
 RF 80.7 69.7 0.095 82.8 78.9 0.315 84.2 77.0 0.137
 EF 79.9 89.4 0.090 80.6 83.7 0.482 84.5 79.0 0.136
 CF 78.6 89.4 0.059 78.9 82.5 0.473 81.5 78.7 0.514
 SF 79.1 69.7 0.182 83.6 72.8 0.012 86.0 73.9 0.009
QLQ-C30 symptom
 FA 30.8 26.3 0.591 31.1 27.6 0.805 27.3 32.0 0.353
 NV 7.4 15.2 0.124 5.2 11.5 0.028 4.7 10.1 0.064
 PA 16.7 21.2 0.521 15.8 17.9 0.633 17.5 16.9 0.871
 DY 13.2 12.1 0.995 13.1 11.4 0.977 12.3 13.5 0.966
 SL 26.3 9.1 0.034 28.2 19.8 0.161 27.9 22.7 0.400
 AP 16.2 18.2 0.963 14.2 16.7 0.897 12.0 18.8 0.114
 CO 25.0 18.2 0.569 26.2 22.8 0.625 25.6 23.5 0.811
 DI 22.8 27.3 0.380 25.0 17.1 0.380 23.4 23.2 0.830
 FI 15.1 15.2 0.662 12.2 16.3 0.272 10.8 17.4 0.124
QLQ-CR29 function
 BI 86.4 88.9 0.908 88.3 85.4 0.455 89.8 84.9 0.094
 ANX 62.1 69.7 0.377 62.7 65.9 0.513 62.3 63.2 0.880
 WEI 75.2 69.7 0.289 74.6 75.6 0.969 78.9 72.1 0.103
 SEXF 17.8 15.2 0.542 16.7 18.4 0.380 20.6 15.9 0.311
QLQ-CR29 symptom
 UF 21.1 25.8 0.498 20.9 20.3 0.852 21.1 21.9 0.933
 BMS 11.6 12.1 0.712 10.6 9.8 0.792 11.8 11.6 0.923
 SF2 19.1 33.3 0.053 19.6 19.4 0.878 24.3 18.5 0.067
 UI 6.4 6.1 0.808 5.1 6.5 0.133 3.5 8.0 0.297
 DY2 2.8 0.0 0.322 1.7 3.3 0.375 0.9 3.5 0.151
 AP2 13.8 15.2 0.866 13.0 13.0 0.668 14.9 13.4 0.990
 BP 8.7 21.2 0.089 6.9 14.2 0.040 7.2 11.6 0.173
 BF 20.1 24.2 0.447 19.5 18.7 0.606 25.4 17.7 0.111
 DM 28.7 30.3 0.664 28.2 27.6 0.940 24.6 31.3 0.100
 HL 17.8 15.2 0.690 14.4 23.3 0.108 4.5 24.7 0.000
 TA 10.8 15.2 0.891 9.0 15.8 0.100 5.4 14.4 0.056
 FL 21.9 21.2 0.928 21.8 20.2 0.737 22.5 21.4 0.913
 FI2 9.3 21.2 0.025 9.8 8.8 0.944 8.1 12.0 0.654
 SS 6.5 21.2 0.025 7.0 8.1 0.777 5.6 9.7 0.181
 EMB 12.7 21.2 0.089 14.4 9.9 0.685 9.9 15.9 0.275
 STO   15.0   0.0 4.8 0.499 0.0 5.6 0.831
 IMP 21.8 9.5 0.142 20.0 20.5 0.691 19.3 20.8 0.708
 DYS 9.5 8.3 0.921 7.7 12.1 0.450 2.4 13.3 0.119
  1. QL2 global health/quality of life, PF physical function, RF role function, EF emotion function, CF cognitive function, SF social function, FA fatigue, NV nausea/vomiting, PA pain, DY dyspnea, SL insomnia, AP appetite loss, CO constipation, DI diarrhea, FI financial difficulty, BI body image, ANX anxiety, WEI weight, SEXF sexual interest, UF urinary frequency, BMS blood and mucus in stool, SF2 stool frequency, UI urinary incontinence, DY2 dysuria, AP2 abdominal pain, BP buttock pain, BF bloating, DM dry mouth, HL hair loss, TA taste, FL flatulence, FI2 faecal incontinence, SS sore skin, EMB embarrassment, STO stoma care problem, IMP importance, DYS dyspareunia
  2. &Wilcoxon rank sum test. P-values in boldface indicated significant between-group difference in quality of life scores
  3. Quality of life scores presented as medium (interquartile range)